Posted in anti-rabbit alexa fluor 488, Antibodies, Assay Kits, Biology Cells, cDNA, Clia Kits, Culture Cells, Devices, DNA, DNA Templates, Elisa Kits, Enzymes, epo elisa kit, Equipments, Exosomes, Gels, human il-2 elisa, human il2 elisa, il15ra elisa, il1rl2 antibody, Isotypes, lmbrd1 antibody, Medium & Serums, NATtrol, Panel, Particles, PCR, Pcr Kits, Peptides, pgf elisa, platelet lysate, Reagents, Recombinant Proteins, Ria Kits, RNA, s100a12 elisa, Test Kits, Vector & Virus, Western Blot

ELISA Kits, a Prototype Multiplex Electrochemoluminescent Assay

gentaur.com

Comparison of Commercial ELISA Kits, a Prototype Multiplex Electrochemoluminescent Assay, and a Multiplex Bead-Based Immunoassay for Detecting a Urine-Based Bladder-Cancer-Associated Diagnostic Signature.

The ability to accurately measure multiple proteins simultaneously in a single assay has the potential to markedly improve the efficiency of clinical tests composed of multiple biomarkers. We investigated the diagnostic accuracy of the two multiplex protein array platforms for detecting a bladder-cancer-associated diagnostic signature in samples from a cohort of 80 subjects (40 with bladder cancer).
Banked urine samples collected from Kyoto and Nara Universities were compared to histologically determined bladder cancer.
  • The concentrations of the 10 proteins (A1AT; apolipoprotein E-APOE; angiogenin-ANG; carbonic anhydrase 9-CA9; interleukin 8-IL-8; matrix metalloproteinase 9-MMP-9; matrix metalloproteinase 10-MMP10; plasminogen activator inhibitor 1-PAI-1; syndecan-SDC1; and vascular endothelial growth factor-VEGF) were monitored using two prototype multiplex array platforms and an enzyme-linked immunosorbent assay (ELISA) according to the manufacturer’s technical specifications.
  • The range for detecting each biomarker was improved in the multiplex assays, even though the lower limit of quantification (LLOQ) was typically lower in the commercial ELISA kits. The area under the receiver operating characteristics (AUROC) of the prototype multiplex assays was reported to be 0.97 for the multiplex bead-based immunoassay (MBA) and 0.86 for the multiplex electrochemoluminescent assay (MEA).
  • The sensitivities and specificities for MBA were 0.93 and 0.95, respectively, and for MEA were 0.85 and 0.80, respectively. Accuracy, positive predictive values (PPV), and negative predictive values (NPV) for MBA were 0.94, 0.95, and 0.93, respectively, and for MEA were 0.83, 0.81, and 0.84, respectively. Based on these encouraging preliminary data, we believe that a multiplex protein array is a viable platform that can be utilized as an efficient and highly accurate tool to quantitate multiple proteins within biologic specimens.
gentaur.com
gentaur.com

PSMB8 Antibody
43134 100ul
EUR 319

PSMB8 Antibody
43134-100ul 100ul
EUR 302.4

PSMB8 Antibody
1-CSB-PA018886GA01HU
  • Ask for price
  • Ask for price
  • 50ul
  • 150ul
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IF

PSMB8 Antibody
1-CSB-PA018886LA01HU
  • Ask for price
  • Ask for price
  • 100ul
  • 50ul
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC; Recommended dilution: IHC:1:20-1:200

PSMB8 Antibody
1-CSB-PA116429
  • Ask for price
  • Ask for price
  • 50ul
  • 100ul
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;ELISA:1:1000-1:2000, WB:1:200-1:1000, IHC:1:25-1:100

PSMB8 Antibody
1-CSB-PA775839
  • Ask for price
  • Ask for price
  • 50ul
  • 100ul
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;ELISA:1:2000-1:5000, WB:1:500-1:2000, IHC:1:25-1:100

PSMB8 Antibody
E043134 100μg/100μl
EUR 255
Description: Available in various conjugation types.

PSMB8 Antibody
BF0434 200ul
EUR 540

PSMB8 Antibody
BF0434-100ul 100ul
EUR 210
Description: WB,IHC,IF/ICC,ELISA

PSMB8 Antibody
BF0434-200ul 200ul Ask for price
Description: WB,IHC,IF/ICC,ELISA

PSMB8 Antibody
BF0434-50ul 50ul
EUR 150
Description: WB,IHC,IF/ICC,ELISA

PSMB8 Antibody
E94054 100μg
EUR 255
Description: Available in various conjugation types.

PSMB8 Antibody
E314816 100ug/200ul
EUR 295
Description: Available in various conjugation types.

PSMB8 Antibody
E97340 100ul
EUR 255
Description: Available in various conjugation types.

PSMB8 Antibody
MBS5312424-01mL 0.1mL
EUR 1070

PSMB8 Antibody
MBS5312424-5x01mL 5x0.1mL
EUR 4655

PSMB8 Antibody
MBS7113266-005mL 0.05mL
EUR 190

PSMB8 Antibody
MBS7113266-01mL 0.1mL
EUR 270

PSMB8 Antibody
MBS7113266-5x01mL 5x0.1mL
EUR 1205

PSMB8 Antibody
MBS7129229-005mL 0.05mL
EUR 190

PSMB8 Antibody
MBS7129229-01mL 0.1mL
EUR 270

PSMB8 Antibody
MBS7129229-5x01mL 5x0.1mL
EUR 1205

PSMB8 Antibody
MBS7129230-005mL 0.05mL
EUR 190

PSMB8 Antibody
MBS7129230-01mL 0.1mL
EUR 270

PSMB8 Antibody
MBS7129230-5x01mL 5x0.1mL
EUR 1205

PSMB8 Antibody
MBS8500013-01mg 0.1mg
EUR 325

PSMB8 Antibody
MBS8500013-01mLAF405L 0.1mL(AF405L)
EUR 565

PSMB8 Antibody
MBS8500013-01mLAF405S 0.1mL(AF405S)
EUR 565

PSMB8 Antibody
MBS8500013-01mLAF610 0.1mL(AF610)
EUR 565

PSMB8 Antibody
MBS8500013-01mLAF635 0.1mL(AF635)
EUR 565

PSMB8 antibody
MBS9405580-01mL 0.1mL
EUR 420

PSMB8 antibody
MBS9405580-5x01mL 5x0.1mL
EUR 1740

PSMB8 Antibody
MBS9416351-01mL 0.1mL
EUR 305

PSMB8 Antibody
MBS9416351-5x01mL 5x0.1mL
EUR 1230

PSMB8 Polyclonal Antibody
A73468
  • Ask for price
  • Ask for price
  • 50 ul
  • 100 ul

PSMB8 Conjugated Antibody
C43134 100ul
EUR 476.4

PSMB8 polyclonal antibody
BS91127 50ul
EUR 398
Description: Rabbit IgG, 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2

PSMB8 polyclonal antibody
BS78214 50ul
EUR 358
Description: 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2

PSMB8 polyclonal antibody
BS8845 50 ul
EUR 358
Description: 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2

PSMB8 Polyclonal Antibody
E-AB-92394-120uL 120uL
EUR 320
Description: Unconjugated

PSMB8 Polyclonal Antibody
E-AB-92394-200uL 200uL
EUR 530
Description: Unconjugated

PSMB8 Polyclonal Antibody
E-AB-92394-60uL 60uL
EUR 200
Description: Unconjugated

PSMB8 Polyclonal Antibody
E-AB-92394-each each Ask for price
Description: Unconjugated

PSMB8 Polyclonal Antibody
E-AB-61655-120uL 120uL
EUR 320
Description: Unconjugated

PSMB8 Polyclonal Antibody
E-AB-61655-200uL 200uL
EUR 530
Description: Unconjugated

PSMB8 Polyclonal Antibody
E-AB-61655-60uL 60uL
EUR 200
Description: Unconjugated

PSMB8 Polyclonal Antibody
E-AB-61655-each each Ask for price
Description: Unconjugated

PSMB8 monoclonal antibody
MB66639 50ul
EUR 275
Description: Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide, pH 7.3.

PSMB8 Polyclonal Antibody
MBS2538339-006mL 0.06mL
EUR 190

PSMB8 Polyclonal Antibody
MBS2538339-012mL 0.12mL
EUR 265

PSMB8 Polyclonal Antibody
MBS2538339-02mL 0.2mL
EUR 415

PSMB8 Polyclonal Antibody
MBS2538339-5x02mL 5x0.2mL
EUR 1835

PSMB8 Polyclonal Antibody
MBS2528965-002mL 0.02mL
EUR 140

PSMB8 Polyclonal Antibody
MBS2528965-006mL 0.06mL
EUR 180

PSMB8 Polyclonal Antibody
MBS2528965-012mL 0.12mL
EUR 260

PSMB8 Polyclonal Antibody
MBS2528965-02mL 0.2mL
EUR 405

PSMB8 Polyclonal Antibody
MBS2528965-5x02mL 5x0.2mL
EUR 1725

PSMB8 Polyclonal Antibody
MBS2527805-002mL 0.02mL
EUR 140

PSMB8 Polyclonal Antibody
MBS2527805-006mL 0.06mL
EUR 180

PSMB8 Polyclonal Antibody
MBS2527805-012mL 0.12mL
EUR 260

PSMB8 Polyclonal Antibody
MBS2527805-02mL 0.2mL
EUR 405

PSMB8 Polyclonal Antibody
MBS2527805-5x02mL 5x0.2mL
EUR 1725

PSMB8 Conjugated Antibody
MBS9451453-01mLAF350 0.1mL(AF350)
EUR 480

PSMB8 Conjugated Antibody
MBS9451453-01mLAF405 0.1mL(AF405)
EUR 480

PSMB8 Conjugated Antibody
MBS9451453-01mLAF488 0.1mL(AF488)
EUR 480

PSMB8 Conjugated Antibody
MBS9451453-01mLAF555 0.1mL(AF555)
EUR 480

PSMB8 Conjugated Antibody
MBS9451453-01mLBiotin 0.1mL(Biotin)
EUR 480

PSMB8 Polyclonal Antibody
RD84433A-120uL 120μL
EUR 360
Description: The proteasome is a multicatalytic proteinase complex with a highly ordered ring-shaped 20S core structure. The core structure is composed of 4 rings of 28 non-identical subunits; 2 rings are composed of 7 alpha subunits and 2 rings are composed of 7 beta subunits. Proteasomes are distributed throughout eukaryotic cells at a high concentration and cleave peptides in an ATP/ubiquitin-dependent process in a non-lysosomal pathway. An essential function of a modified proteasome, the immunoproteasome, is the processing of class I MHC peptides. This gene encodes a member of the proteasome B-type family, also known as the T1B family, that is a 20S core beta subunit. This gene is located in the class II region of the MHC (major histocompatibility complex). Expression of this gene is induced by gamma interferon and this gene product replaces catalytic subunit 3 (proteasome beta 5 subunit) in the immunoproteasome. Proteolytic processing is required to generate a mature subunit. Two alternative transcripts encoding two isoforms have been identified; both isoforms are processed to yield the same mature subunit.

PSMB8 Polyclonal Antibody
RD84433A-200uL 200μL
EUR 630
Description: The proteasome is a multicatalytic proteinase complex with a highly ordered ring-shaped 20S core structure. The core structure is composed of 4 rings of 28 non-identical subunits; 2 rings are composed of 7 alpha subunits and 2 rings are composed of 7 beta subunits. Proteasomes are distributed throughout eukaryotic cells at a high concentration and cleave peptides in an ATP/ubiquitin-dependent process in a non-lysosomal pathway. An essential function of a modified proteasome, the immunoproteasome, is the processing of class I MHC peptides. This gene encodes a member of the proteasome B-type family, also known as the T1B family, that is a 20S core beta subunit. This gene is located in the class II region of the MHC (major histocompatibility complex). Expression of this gene is induced by gamma interferon and this gene product replaces catalytic subunit 3 (proteasome beta 5 subunit) in the immunoproteasome. Proteolytic processing is required to generate a mature subunit. Two alternative transcripts encoding two isoforms have been identified; both isoforms are processed to yield the same mature subunit.

PSMB8 Polyclonal Antibody
RD84433A-60uL 60μL
EUR 204
Description: The proteasome is a multicatalytic proteinase complex with a highly ordered ring-shaped 20S core structure. The core structure is composed of 4 rings of 28 non-identical subunits; 2 rings are composed of 7 alpha subunits and 2 rings are composed of 7 beta subunits. Proteasomes are distributed throughout eukaryotic cells at a high concentration and cleave peptides in an ATP/ubiquitin-dependent process in a non-lysosomal pathway. An essential function of a modified proteasome, the immunoproteasome, is the processing of class I MHC peptides. This gene encodes a member of the proteasome B-type family, also known as the T1B family, that is a 20S core beta subunit. This gene is located in the class II region of the MHC (major histocompatibility complex). Expression of this gene is induced by gamma interferon and this gene product replaces catalytic subunit 3 (proteasome beta 5 subunit) in the immunoproteasome. Proteolytic processing is required to generate a mature subunit. Two alternative transcripts encoding two isoforms have been identified; both isoforms are processed to yield the same mature subunit.

PSMB8 Antibody (N-term)
MBS9213569-008mL 0.08mL
EUR 210

PSMB8 Antibody (N-term)
MBS9213569-04mL 0.4mL
EUR 430

PSMB8 Antibody (N-term)
MBS9213569-5x04mL 5x0.4mL
EUR 1910

PSMB8 Antibody, HRP conjugated
1-CSB-PA018886LB01HU
  • Ask for price
  • Ask for price
  • 100ul
  • 50ul
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human. This antibody is HRP conjugated. Tested in the following application: ELISA

PSMB8 Antibody, HRP Conjugated
MBS7113267-005mL 0.05mL
EUR 190

PSMB8 Antibody, HRP Conjugated
MBS7113267-01mL 0.1mL
EUR 270

PSMB8 Antibody, HRP Conjugated
MBS7113267-5x01mL 5x0.1mL
EUR 1205

PSMB8 Antibody, FITC conjugated
1-CSB-PA018886LC01HU
  • Ask for price
  • Ask for price
  • 100ul
  • 50ul
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human. This antibody is FITC conjugated. Tested in the following application: ELISA

PSMB8 Antibody, FITC Conjugated
MBS7113268-005mL 0.05mL
EUR 190

Comparison of Rapid Anti-HCV Multi-sure Kit with Gold Standard ELISA.

To compare the diagnostic yield of Multi-sure rapid HCV (hepatitis C virus) kit with ELISA.Comparative study.Pakistan Health Research Council, specialised research center for gastroenterology and hepatology, from August 2016 to January 2017.A modified rapid anti-HCV kit was compared with ELISA. This rapid kit is multi-parameter qualitative immune chromatographic kit for the in-vitro detection of antibodies to HCV in human blood.

  • Patients who came to PHRC, were tested using anti-HCV ELISA, and their test was run simultaneously on multi-sure HCV rapid kit were included in the study. Each positive and negative sample was included in this study. SPSS software was adapted for data analysis.A total of 420 samples were collected.
  • Among them, 255 (61%) were of male and 165 (39%) were of female patients. Mean age was 35 ± 14.33 years. All the samples run for anti-HCV on ELISA were also run on multi-sure rapid kit. It is evident that 22.4% were reactive on ELISA and 23.6% were reactive on rapid kit, while 75.5% were non-reactive on ELISA and 68.1% were non-reactive on rapid kit.
  • Borderline positive results were seen in 2.1% on ELISA and 5.0% on rapid kit. Sensitivity of rapid kit was 87.2%, specificity 89.3% with 82.8% positive predictive value and 98.9% negative predictive value.Multi-sure kit showed significantly, less non-reactive and more borderline results as compared to ELISA.
  • Comparison of multi-sure rapid kit with ELISA showed that core antibody can be used as an alternate marker for ELISA. Other non-structural proteins including NS3, NS4 and NS5 were found to be less significant. So, it is concluded that this rapid kit may not be recommended as an alternative of ELISA, except for places where ELISA is not available.

Monitoring of infliximab trough levels and anti-infliximab antibodies in inflammatory bowel diseases: A comparison of three commercially available ELISA kits.

There are many studies presenting data of biologics and several ELISA kits commercially available for monitoring infliximab serum trough levels (s-IFXt) and anti-drug antibodies (ADAb). We propose to compare technical characteristics and results of three different assays on a cohort of 35 patients under infliximab (IFX) and suffering from inflammatory bowel disease (IBD).s-IFXt and ADAb were systematically measured with three ELISA kits: Lisa-Tracker® Duo infliximab (Theradiag®), Ridascreen® IFX Monitoring (R-Biopharm AG®) and Promonitor® IFX (Progenika Biopharma SA®).

The main technical features that differed between kits for measuring s-IFXt were: (i) TNF coating, (ii) immune complexes revelation strategy and/or (iii) interference with other anti-TNFα agents. For kits measuring ADAb, they were revelation steps and unit of results.

There was an excellent mathematical correlation of s-IFXt between assays however Bland-Altman analysis denoted (i) s-IFXt were on average 48 to 69% higher in Ridascreen® than in the other two assays, and (ii) elevated s-IFXt were higher with Promonitor® compared to Lisa-Tracker®.

As a consequence, there were some substantial discrepancies between assays for classification of s-IFXt into concentration ranges. Despite unstandardized units, pairwise qualitative comparison showed a perfect agreement between the three pairs of ADAb assays.

Our data show that the evaluated assays are not quantitatively interchangeable due to substantial variations in some results that could lead, for some patients, to divergent therapeutic decisions. We remind to be cautious when comparing study results issued from different kits and recommend using the same assay for the longitudinal follow-up of IBD patients

Brent